Array Biopharma Inc.

Genentech, Inc.

Genetech, Inc.

Covenentech, Inc.

Genertech, Inc.

Tang, Tony P.

Hentemann, Martin F.

Blake, James F.

Banka, Anna

Wallace, Eli M.

Bencsik, Josef R.

Mitchell, Ian S.

Xu, Rui

Sammond, Douglas Mccord

Fong, Kin Chiu

Anna L Banka

James F Blake

Eli M Wallace

Rui Xu

Ian S Mitchell

Josef R Bencsik

Stephen T Schlachter

Jun Liang

Nicholas C Kallan

Brian Salvatore Safina

Tony P Tang

Dengming Xiao

Keith Lee Spencer

Martin F Hentemann

Christine Chabot

Steven Huy Do

Birong Zhang

Kin Chiu Fong

Jun M Li

Douglas McCord Sammond

James M Graham

Jun Li

Eli W Wallace

The present invention provides compounds of Formula I including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.  Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as Akt protein kinase inhibitors

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I:  Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I). 

5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors

The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer. 

Growing community of inventors

Longmont, CO, United States of America

Anna L Banka